Tema ETFs’s Celldex Therapeutics CLDX Stock Holding History

Tema ETFs’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-29,480	Closed	-$745K	–	153
2024 Q4	$745K	Buy	+29,480	New	+$801K	0.31%	75

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tema ETFs's CLDX Position: Q1 2025 in Review

Tema ETFs sold out of Celldex Therapeutics (CLDX) in Q1 2025, closing a stake of 29,480 shares — an estimated $745K sold.

Tema ETFs first reported a position in CLDX in Q4 2024 and held it in 1 quarter. The position peaked at $745K in Q4 2024. 171 funds tracked by Wall St. Rank hold CLDX as of Q1 2025.

Tema ETFs reported no remaining Celldex Therapeutics position as of Q1 2025 after selling out during the quarter.
Tema ETFs sold 29,480 Celldex Therapeutics shares in Q1 2025, an estimated $745K.
Tema ETFs first reported a position in Celldex Therapeutics in Q4 2024 and held it in 1 quarter.
Tema ETFs's Celldex Therapeutics position peaked at $745K in Q4 2024.
171 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2025.

Based on Tema ETFs's 13F filing for Q1 2025, filed 14 May 2025.